Neuronal substrate and effective connectivity of abnormal movement sequencing in schizophrenia

Progress in Neuro-psychopharmacology & Biological Psychiatry
Petra ZemankovaTomas Kasparek

Abstract

Movement sequencing difficulties are part of the neurological soft signs (NSS), they have high clinical value because they are not always present in schizophrenia. We investigated the neuronal correlates of movement sequencing in 24 healthy controls and 24 schizophrenia patients, with (SZP SQ+) or without (SZP SQ-) sequencing difficulties. We characterized simultaneous and lagged functional connectivity between brain regions involved in movement sequencing using psychophysiological interaction (PPI) and the Granger causality modeling (GCM), respectively. Left premotor cortex (PMC) and superior parietal lobule (SPL) were specifically activated during sequential movements in all participants. Right PMC and precuneus, ipsilateral to the hand executing the task, activated during sequential movements only in healthy controls and SZP SQ-. SZP SQ+ showed hyperactivation in contralateral PMC, as compared to the other groups. PPI analysis revealed a deficit in inhibitory connections within this fronto-parietal network in SZP SQ+ during sequential task. GCM showed a significant lagged effective connectivity from right PMC to left SPL during task and rest periods in all groups and from right PMC to right precuneus in SZP SQ+ group only. B...Continue Reading

References

May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Nov 5, 1997·NeuroImage·K J FristonR J Dolan
Feb 15, 2001·Archives of General Psychiatry·B KirkpatrickW T Carpenter
Sep 14, 2001·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A SolodkinS L Small
Apr 18, 2002·Brain Research. Cognitive Brain Research·Bernhard HaslingerHenning Boecker
Apr 11, 2003·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Friedhelm HummelChristian Gerloff
Oct 11, 2003·Urology·Penny S Brucker, David Cella
Mar 1, 2005·NeuroImage·Alard RoebroeckRainer Goebel
Jun 17, 2005·Schizophrenia Bulletin·Igor BombinRobert W Buchanan
Aug 19, 2005·Proceedings of the National Academy of Sciences of the United States of America·Stéphane LehéricyJulien Doyon
Jul 16, 2008·Schizophrenia Research·T WobrockP Falkai
Apr 21, 2009·Schizophrenia Bulletin·Raymond C K ChanYa Wang
Mar 6, 2010·NeuroImage·Steven L Bressler, Anil K Seth
Sep 25, 2010·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Michele RibolsiGiacomo Koch
Apr 12, 2011·NeuroImage·Pedro A Valdes-SosaKarl Friston
Jan 1, 2011·Brain Connectivity·Karl J Friston
Aug 21, 2012·Psychiatry Research·Mario AltamuraAlessandro Bertolino
Dec 26, 2012·Current Opinion in Neurobiology·Karl FristonAnil K Seth
Mar 8, 2013·JAMA Psychiatry·Aristotle N VoineskosBenoit H Mulsant
Jul 19, 2013·PloS One·Xiaotong WenMingzhou Ding
Jan 27, 2015·Behavioural Brain Research·Deborah J Serrien, Michiel M Sovijärvi-Spapé
Nov 26, 2015·Neuroscience and Biobehavioral Reviews·Sebastian OcklenburgMarco Hirnstein

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here